Access to Information Orders
Decision Information
NATURE OF THE APPEAL: The Ministry of Health and Long-Term Care (the Ministry) received a request under the Freedom of Information and Protection of Privacy Act (the Act ) for access to records prepared by or for the Ministry in relation to: … the possible introduction of a generic pharmaceutical product that would include the active ingredient omeprazole, or omeprazole magnesium and/or claim boiequivalence with [a named drug]. In response, the Ministry identified 10 responsive records and advised the requester that it was granting partial access to one record (Record 1), and denying access to the remaining portions of Record 1 and the other nine records in full on the basis of the exemptions at sections 13 (advice or recommendations), 17 (third party commercial information), 18 (economic interests of government) and/or 21 (invasion of privacy) of the Act . The Ministry also provided the appellant with an index describing the responsive records and indicating which exemptions applied to which records. The requester, now the appellant, appealed the Ministry’s decision. During the mediation stage of the appeal, the appellant indicated that he was not seeking access to the names, addresses and other personal identifiers of individual drug reviewers. As a result, this information and the section 21 exemption are no longer at issue. Mediation was not successful in resolving the remaining issues, and this appeal was transferred to the adjudication stage of the process. A Notice of Inquiry was sent to the Ministry and two affected parties. Representations were received from all of these parties. The Ministry and both of the affected parties provided representations on the issues. One affected party (affected party A) provided extensive representations on the issues with respect to the record relating to it (Record 1). The other affected party (affected party B) provided brief representations, identifying that the information contained in the records was the private, proprietary and confidential information of affected party B, which had been submitted to the Ministry on the understanding that it would remain confidential. Affected party B also identified a concern that disclosure of the records may cause competitors to interfere with the process, and may create a competitive disadvantage for affected party B. I then sent the Notice of Inquiry, along with the non-confidential portions of the representations of the Ministry and affected party A, and a summary of affected party B’s position, to the appellant. The appellant also provided representations on the issues. RECORDS: There are ten records at issue in this appeal. They include correspondence (including attachments) between the affected parties and the Ministry’s Drug Programs Branch (the DPB), correspondence between the DPB and a drug reviewer, the drug reviewer’s report, and an internal e-mail between DPB staff. DISCUSSION: THIRD PARTY INFORMATION The Ministry and the affected parties take the position that the mandatory exemption in section 17(1)(a), (b) and/or (c) applies to the information at issue contained in Records 1-10. Section 17(1) states: A head shall refuse to disclose a record that reveals a trade secret or scientific, technical, commercial, financial or labour relations information, supplied in confidence implicitly or explicitly, where the disclosure could reasonably be expected to, (a) prejudice significantly the competitive position or interfere significantly with the contractual or other negotiations of a person, group of persons, or organization; (b) result in similar information no longer being supplied to the institution where it is in the public interest that similar information continue to be so supplied; (c) result in undue loss or gain to any person, group, committee or financial institution or agency; or For a record to qualify for exemption under sections 17(1)(a), (b) or (c), the Ministry and/or the affected parties must satisfy each part of the following three-part test: the record must reveal information that is a trade secret or scientific, technical, commercial, financial or labour relations information; and the information must have been supplied to the Ministry in confidence, either implicitly or explicitly; and the prospect of disclosure of the record must give rise to a reasonable expectation that one of the harms specified in (a), (b) or (c) of subsection 17(1) will occur. [Orders 36, P-373, M-29 and M-37] Part 1 of the Section 17(1) Test - Type of Information Trade secret Both the Ministry and affected party A have submitted that the records contain information which qualifies as a “trade secret” for the purpose of section 17(1). Previous orders have defined that term as follows: "trade secret" means information including but not limited to a formula, pattern, compilation, programme, method, technique, or process or information contained or embodied in a product, device or mechanism which (i) is, or may be used in a trade or business, (ii) is not generally known in that trade or business, (iii) has economic value from not being generally known, and (iv) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy. (See Orders M-29, PO-2010) Affected party A takes the position that the information contained in Record 1 reveals “trade secrets” belonging to that affected party. It states: The [affected party A] information discloses [affected party A’s] secret strategy for launching its proposed … product. The Brand Name Drug Manufacturer or potential competitor learning about these plans could pre-empt [affected party A’s] product launch with additional marketing efforts, prevent [affected party A] from gaining any significant market share, and thereby cause it significant economic damage…. [Affected party A’s] plans … are not known in the marketplace, and [affected party A] has used reasonable measures to protect the secrecy of such plans. Affected party A then refers in its confidential representations to the specific information which it considers its “trade secret”. The appellant makes no submissions on whether the information reveals a trade secret. In Order PO-2097, Adjudicator Hale had to decide whether information similar to that at issue in this appeal constituted “trade secrets” for the purpose of section 17 of the Act . He stated: In my view, the types of information contained in the records at issue in this appeal do not constitute “trade secrets” for the purposes of section 17(1). Despite the evidence tendered by the affected party, I find that the strategies and the methodologies relating to governmental relations which are included in the records are common throughout the pharmaceutical industry and are not
Decision Content
NATURE OF THE APPEAL:
The Ministry of Health and Long-Term Care (the Ministry) received a request under the Freedom of Information and Protection of Privacy Act (the Act) for access to records prepared by or for the Ministry in relation to:
… the possible introduction of a generic pharmaceutical product that would include the active ingredient omeprazole, or omeprazole magnesium and/or claim boiequivalence with [a named drug].
In response, the Ministry identified 10 responsive records and advised the requester that it was granting partial access to one record (Record 1), and denying access to the remaining portions of Record 1 and the other nine records in full on the basis of the exemptions at sections 13 (advice or recommendations), 17 (third party commercial information), 18 (economic interests of government) and/or 21 (invasion of privacy) of the Act. The Ministry also provided the appellant with an index describing the responsive records and indicating which exemptions applied to which records.
The requester, now the appellant, appealed the Ministry’s decision.
During the mediation stage of the appeal, the appellant indicated that he was not seeking access to the names, addresses and other personal identifiers of individual drug reviewers. As a result, this information and the section 21 exemption are no longer at issue.
Mediation was not successful in resolving the remaining issues, and this appeal was transferred to the adjudication stage of the process. A Notice of Inquiry was sent to the Ministry and two affected parties. Representations were received from all of these parties.
The Ministry and both of the affected parties provided representations on the issues. One affected party (affected party A) provided extensive representations on the issues with respect to the record relating to it (Record 1). The other affected party (affected party B) provided brief representations, identifying that the information contained in the records was the private, proprietary and confidential information of affected party B, which had been submitted to the Ministry on the understanding that it would remain confidential. Affected party B also identified a concern that disclosure of the records may cause competitors to interfere with the process, and may create a competitive disadvantage for affected party B.
I then sent the Notice of Inquiry, along with the non-confidential portions of the representations of the Ministry and affected party A, and a summary of affected party B’s position, to the appellant. The appellant also provided representations on the issues.
RECORDS:
There are ten records at issue in this appeal. They include correspondence (including attachments) between the affected parties and the Ministry’s Drug Programs Branch (the DPB), correspondence between the DPB and a drug reviewer, the drug reviewer’s report, and an internal e-mail between DPB staff.
DISCUSSION:
THIRD PARTY INFORMATION
The Ministry and the affected parties take the position that the mandatory exemption in section 17(1)(a), (b) and/or (c) applies to the information at issue contained in Records 1-10. Section 17(1) states: